Limb-Girdle Muscular Dystrophy (LGMD) Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Limb-Girdle Muscular Dystrophy (LGMD) Epidemiology Forecast Report Coverage

Expert Market Research's “Limb-Girdle Muscular Dystrophy (LGMD) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of limb-girdle muscular dystrophy (LGMD). It projects the future incidence and prevalence rates of limb-girdle muscular dystrophy (LGMD) cases across various populations. The study covers age, gender, and type as major determinants of the limb-girdle muscular dystrophy (LGMD) population. The report highlights patterns in the prevalence of limb-girdle muscular dystrophy (LGMD) over time and projects future trends based on multiple variables.

Limb-Girdle Muscular Dystrophy (LGMD) Understanding: Disease Overview

Limb-girdle muscular dystrophy (LGMD) comprises a group of genetically inherited disorders characterized by progressive weakness of the hip and shoulder muscles. It results from mutations in over 30 genes affecting sarcolemmal stability, repair, or metabolism. Symptoms typically appear in late childhood or adulthood, leading to mobility challenges and, in some cases, cardiopulmonary involvement. The disease affects both sexes equally and progresses variably depending on subtype. Diagnosis is established through genetic testing, electromyography, and muscle biopsy confirming dystrophic changes.

Limb-Girdle Muscular Dystrophy (LGMD) Epidemiology Perspective

The limb-girdle muscular dystrophy (LGMD) epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the limb-girdle muscular dystrophy (LGMD) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for limb-girdle muscular dystrophy (LGMD) and their trends. The limb-girdle muscular dystrophy (LGMD) detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Orphanet (2024), the estimated global prevalence of limb-girdle muscular dystrophy (LGMD) ranges between 1 and 9 per 100,000 individuals, classifying it as a rare disease.
• LGMD typically manifests between childhood and mid-adulthood (10-30 years), though onset varies by subtype. CAPN3-related (LGMDR1) often begins in adolescence, while ANO5-related (LGMDR12) may appear later in adulthood.
• Limb-girdle muscular dystrophy affects both sexes equally, as most forms are autosomal recessive or dominant with no X-linked inheritance.

Read more about this report - Request a Free Sample

Country-wise Limb-Girdle Muscular Dystrophy (LGMD) Epidemiology Segment

The limb-girdle muscular dystrophy (LGMD) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, limb-girdle muscular dystrophy (LGMD) remains a rare neuromuscular disorder, affecting an estimated 2 per 100,000 individuals according to the Cleveland Clinic. The Muscular Dystrophy Association (MDA) reports that approximately 5,000 Americans currently live with the condition. The prevalence varies by genetic subtype, with calpainopathy (CAPN3) and dysferlinopathy (DYSF) being among the most frequently identified in U.S. cohorts. Increased access to genetic testing has improved diagnosis, revealing broader subtype diversity and aiding in targeted therapeutic research nationwide.

Limb-Girdle Muscular Dystrophy (LGMD): Treatment Overview

Management of limb-girdle muscular dystrophy is primarily supportive, focusing on physiotherapy, orthopedic interventions, and respiratory monitoring. Corticosteroids are sometimes used for select subtypes to slow progression. Emerging gene therapies and exon-skipping technologies target molecular defects, particularly in CAPN3- and DYSF-related LGMD. Recent advances include adeno-associated virus (AAV)-based gene replacement therapies showing promise in clinical trials. Assistive mobility devices, cardiac care, and multidisciplinary rehabilitation improve quality of life and functional outcomes. No curative therapy exists, but research in precision medicine is accelerating therapeutic innovation.

Key Questions Answered

• What are the key findings of limb-girdle muscular dystrophy (LGMD) epidemiology in the 8 major markets?
• What will be the total number of patients with limb-girdle muscular dystrophy (LGMD) across the 8 major markets during the forecast period?
• What was the country-wise limb-girdle muscular dystrophy (LGMD) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of limb-girdle muscular dystrophy (LGMD) during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of limb-girdle muscular dystrophy (LGMD) during the forecast period of 2026-2035?
• What are the currently available treatments for limb-girdle muscular dystrophy (LGMD)?
• What are the disease risks, signs, symptoms, and unmet needs of limb-girdle muscular dystrophy (LGMD)?

Scope of the Limb-Girdle Muscular Dystrophy (LGMD) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of limb-girdle muscular dystrophy (LGMD) based on several factors.
• Limb-Girdle Muscular Dystrophy (LGMD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The limb-girdle muscular dystrophy (LGMD) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Duchenne Muscular Dystrophy (DMD) Treatment Market

Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast

Facioscapulohumeral Muscular Dystrophy Pipeline Analysis Report